ALK and anaplastic large cell lymphoma: Twenty-four percent of ALK-negative ALCL shows aberrant levels of truncated Erb-B2 receptor tyrosine kinase 4 (ERBB4) transcripts, and ERB kinase inhibitors, such as cetuximab and gefitinib, are potential therapies.